

# **China Cancer Drugs Market, by Drugs [Cytotoxic Drugs (Antimetabolites, Plant Alkaloids, Alkylating Agents), Targeted Drugs, Monoclonal Antibiotics, Hormonal Drugs, Traditional Chinese Medicine (TCM), & Others], Cancer (Lung, Stomach, Breast, Esophageal, Liver & Others), Therapy (Chemotherapy, Targeted Therapy, Hormonal Therapy & Others), Companies (Merck, Celgene, Eli Lilly, Roche & Sino BioPharma)**

<https://marketpublishers.com/r/C866B3E2983EN.html>

Date: August 2018

Pages: 0

Price: US\$ 1,990.00 (Single User License)

ID: C866B3E2983EN

## **Abstracts**

Anti-Cancer drugs are the drugs which are used to reduce or prevent the cell proliferation of cancerous tissues. China Cancer Drugs Market is projected to reach US\$ 30 Billion by the year 2024; owing to the increasing prevalence of various types of cancer, changing lifestyle & dietary habits, growing aging population, rising demand of targeted drug therapy and the patent expiration of key cancer drugs. Cancer is one of the leading causes of death worldwide and is a major public health burden in both developed and developing countries.

The rate of cancer incidences in China is exploding very rapidly; nearly 4 million people diagnosed and almost 3 million died from it. For instance; due to increasing air pollution over the last couple of years, lung cancer has increased 50% in Beijing only. Anticancer drugs act like an inhibitor that prevents cancer cells to grow.

In addition; factors like growing awareness regarding cancer diagnosis & treatment, advancement in cancer drugs and therapies, rise in cancer awareness programs like breast cancer screening, investment in healthcare infrastructure are expected to drive

China anti-cancer drugs market positively over the forecast period. However, major side-effects of cancer drugs and its high cost are certainly restraining the China anti-cancer drugs market to reach its full potential.

Renub Research report titled “China Cancer Drugs Market, by Drugs [Cytotoxic Drugs (Antimetabolites, Plant Alkaloids, Alkylating Agents), Targeted Drugs, Monoclonal Antibiotics, Hormonal Drugs, Traditional Chinese Medicine (TCM), & Others], Cancer (Lung, Stomach, Breast, Esophageal, Liver & Others), Therapy (Chemotherapy, Targeted Therapy, Hormonal Therapy & Others), Companies (Merck, Celgene, Eli Lilly, Roche & Sino BioPharma)” provides a complete analysis of China Anti-Cancer Drugs Market.

**By Drugs – Cytotoxic Drugs leads the Cancer Drugs Market in China**

Based on the drugs type, China cancer drugs market is segmented into cytotoxic drugs, targeted drugs, Monoclonal Antibiotics, hormonal drugs, TCM and Others. The cytotoxic drugs segment is further classified into Antimetabolites, Plant Alkaloids and Alkylating Agents.

**By Cancer – Lungs Cancer accounts for the largest share of China Cancer Drugs Market**

On the basis of cancer type, China cancer drugs market is segmented into Lung, Stomach, Breast, Esophageal, Liver & Others. Lung, Breast and Stomach Cancer dominates the China anti-cancer drugs market and is expected to do so in the near future.

**By Therapy – Targeted Therapy is expected to grow significantly during the forecast period**

By therapy type, the China anti-cancer drugs market is segmented into chemotherapy, targeted therapy, hormonal therapy and others. Chemotherapy and targeted therapy together held the major share of China cancer drugs market.

**Company Analysis**

Some of the prominent companies competing in the China Anti-Cancer Drugs Market, and profiled in the report include Merck, Celgene, Eli Lilly, Roche and Sino BioPharma.

This market research report provides a complete analysis of the China Cancer Drugs Market, Growth Drivers, Challenges, and their projections for the upcoming years.

## By Drugs

### Cytotoxic Drugs

- Antimetabolites

- Plant Alkaloids

- Alkylating Agents

### Targeted Drugs

- Monoclonal Antibiotics

- Hormonal Drugs

- Traditional Chinese Medicine (TCM)

- Others

## By Cancer

- Lung Cancer

- Stomach Cancer

- Breast Cancer

- Esophageal Cancer

- Liver Cancer

- Others

## By Therapy

Chemotherapy

Targeted Therapy

Hormonal Therapy

Others

## Companies Covered in the Report

Merck

Celegene

Eli Lilly

Roche

Sino BioPharma

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. CHINA CANCER DRUGS MARKET**

### **3. MARKET SHARE – CHINA ANTI-CANCER DRUGS**

3.1 By Drugs

3.2 By Cancer

3.3 By Therapy

### **4. DRUGS – CHINA CANCER MARKET**

4.1 Cytotoxic Drugs

4.1.1 Antimetabolites

4.1.2 Plant Alkaloids

4.1.3 Alkylating Agents

4.2 Targeted Drugs

4.3 Monoclonal Antibiotics

4.4 Hormonal Drugs

4.5 Traditional Chinese Medicine (TCM)

4.6 Others

### **5. CANCER TYPE – MARKET**

5.1 Lung Cancer

5.2 Stomach Cancer

5.3 Breast Cancer

5.4 Esophageal Cancer

5.5 Liver Cancer

5.6 Others

### **6. THERAPY – CHINA CANCER MARKET**

6.1 Chemotherapy

6.2 Targeted Therapy

6.3 Hormonal Therapy

6.4 Others

## **7. COMPANY ANALYSIS**

### 7.1 Merck

7.1.1 Company Overview

7.1.2 Financial Insights

### 7.2 Celgene

7.2.1 Company Overview

7.2.2 Financial Insights

### 7.3 Eli Lilly

7.3.1 Company Overview

7.3.2 Financial Insights

### 7.4 Roche

7.4.1 Company Overview

7.4.2 Financial Insights

### 7.5 Sino BioPharma

7.5.1 Company Overview

7.5.2 Financial Insights

## **8. GROWTH DRIVERS**

8.1 Growing Awareness towards Cancer Diagnosis and Treatment

8.2 Increasing Use of Targeted Therapy

8.3 Increasing Research and Development Activities

8.4 Cutting Import Duties on Cancer Drugs

## **9. CHALLENGES**

9.1 High Cost of Cancer Drugs

9.2 Major Side Effects of Cancer Treatment

## List Of Figures

### LIST OF FIGURES

Figure 2-1: China – Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 2-2: China – Forecast for Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 3-1: By Drugs – China Anti-Cancer Drugs Market Share (%), 2011 – 2017

Figure 3-2: By Drugs – Forecast for China Anti-Cancer Drugs Market Share (%), 2018 – 2024

Figure 3-3: By Cancer – China Anti-Cancer Drugs Market Share (%), 2011 – 2017

Figure 3-4: By Cancer – Forecast for China Anti-Cancer Drugs Market Share (%), 2018 – 2024

Figure 3-5: By Therapy – China Anti-Cancer Drugs Market Share (%), 2011 – 2017

Figure 3-6: By Therapy – Forecast for China Anti-Cancer Drugs Market Share (%), 2018 – 2024

Figure 4-1: Cytotoxic Drugs – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 4-2: Cytotoxic Drugs – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 4-3: Antimetabolites – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 4-4: Antimetabolites – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 4-5: Plant Alkaloids – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 4-6: Plant Alkaloids – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 4-7: Alkylating Agents – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 4-8: Alkylating Agents – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 4-9: Targeted Drugs – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 4-10: Targeted Drugs – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 4-11: Monoclonal Antibiotics – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 4-12: Monoclonal Antibiotics – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 4-13: Hormonal Drugs – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 4-14: Hormonal Drugs – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 4-15: Traditional Chinese Medicine (TCM) – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 4-16: Traditional Chinese Medicine (TCM) – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 4-17: Others – China Anti-Cancer Drugs Market (Million US\$), 2011 – 2017

Figure 4-18: Others – Forecast for China Anti-Cancer Drugs Market (Million US\$), 2018 – 2024

Figure 5-1: Lung Cancer – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 5-2: Lung Cancer – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 5-3: Stomach Cancer – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 5-4: Stomach Cancer – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 5-5: Breast Cancer – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 5-6: Breast Cancer – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 5-7: Esophageal Cancer – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 5-8: Esophageal Cancer – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 5-9: Liver Cancer – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 5-10: Liver Cancer – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 5-11: Others – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 5-12: Others – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 6-1: Chemotherapy – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 6-2: Chemotherapy – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 6-3: Targeted Therapy – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 6-4: Targeted Therapy – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024



Figure 6-5: Hormonal Therapy – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 6-6: Hormonal Therapy – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 6-7: Others – China Anti-Cancer Drugs Market (Billion US\$), 2011 – 2017

Figure 6-8: Others – Forecast for China Anti-Cancer Drugs Market (Billion US\$), 2018 – 2024

Figure 7-1: Merck – Global Oncology Product Sales (Million US\$), 2011 – 2017

Figure 7-2: Merck – Forecast for Global Oncology Product Sales (Million US\$), 2018 – 2024

Figure 7-3: Celgene – Global Net Product Sales (Million US\$), 2011 – 2017

Figure 7-4: Celgene – Forecast for Global Net Product Sales (Million US\$), 2018 – 2024

Figure 7-5: Eli Lilly – Global Oncology Revenue (Million US\$), 2011 – 2017

Figure 7-6: Eli Lilly – Forecast for Global Oncology Revenue (Million US\$), 2018 – 2024

Figure 7-7: Roche – Global Oncology Products Sales (Million US\$), 2011 – 2017

Figure 7-8: Roche – Forecast for Global Oncology Products Sales (Million US\$), 2018 – 2024

Figure 7-9: Sino BioPharma – Global Oncology Revenue (Million US\$), 2012 – 2017

Figure 7-10: Sino BioPharma – Forecast for Global Oncology Revenue (Million US\$), 2018 – 2024

## I would like to order

Product name: China Cancer Drugs Market, by Drugs [Cytotoxic Drugs (Antimetabolites, Plant Alkaloids, Alkylating Agents), Targeted Drugs, Monoclonal Antibiotics, Hormonal Drugs, Traditional Chinese Medicine (TCM), & Others], Cancer (Lung, Stomach, Breast, Esophageal, Liver & Others), Therapy (Chemotherapy, Targeted Therapy, Hormonal Therapy & Others), Companies (Merck, Celgene, Eli Lilly, Roche & Sino BioPharma)

Product link: <https://marketpublishers.com/r/C866B3E2983EN.html>

Price: US\$ 1,990.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C866B3E2983EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970